Background: Mice with trangenes that express mutations in the gene for cyto
solic copper/zinc superoxide dismutase (SOD1) develop motor neuron degenera
tion resembling human ALS. Neurophilin ligands are small molecules that pro
mote neurite outgrowth. Objective: To test the hypothesis that treatment wi
th two neurophilin ligands increases survival in these ALS mice by slowing
the loss of motor neurons and increasing the sizes of motor units. Methods:
Transgenic mice hemizygous for the G93A mutation were untreated or treated
from 30 days of age with one of two doses of two neurophilin ligands (V-13
,670; V-10,367, Vertex Pharmaceuticals, Boston, MA). Onset of behavioral ab
normalities and survival were recorded. Motor unit number estimation (MUNE)
was performed every 21 days starting at age 60 days. Results: In control a
nimals, disease onset occurred at 77.0 days of age and death occurred at 13
7 days of age. Neither neurophilin ligand affected the disease course. In c
ontrol animals, MUNE declined with time beginning before behavioral abnorma
lities were noted, and motor unit size increased concomitantly. There was n
o effect of drug on motor unit loss as assessed by MUNE; however, motor uni
t size increased more rapidly and to a greater degree in animals treated wi
th V-13,670. Conclusion: As in human ALS, the transgenic ALS mice show phys
iologic changes in the motor unit prior to the development of clinical sign
s: MUNE declines as motor unit size increases. Although neither neurophilin
ligand significantly affected survival, one produced an increase in motor
unit size. The fact that survival was not altered by the increase in motor
unit size may reflect the rapid disease course in this animal model.